Mo Bashir

Prof. Mo Bashir

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MBMo Bashir
Mo Bashir
AHAmer Harky
Amer Harky
MFMatthew Fok
Matthew Fok
MSMatthew Shaw
Matthew Shaw
GHGraeme L. Hickey
Graeme L. Hickey
AOAung Oo
Aung Oo

26 July 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
CHCallum Howard
Callum Howard
JSJonathan Sheridan
Jonathan Sheridan
LPLeonardo Picca
Leonardo Picca
SRSihab Reza
Sihab Reza
TSTristan Smith
Tristan Smith
MIMohammed Idhrees
Mohammed Idhrees
Background Type B aortic dissection (TBAD), is defined as a dissection involving the aorta distal to left subclavian artery with the ascending aorta and the aortic arch not affected. TBAD is classified due to the time frame and presence of complications. Complicated TBAD (co-TBAD) patients have a greater mortality rate than uncomplicated TBAD (un-TBAD) and thoracic endovascular aortic repair (TEVAR) is considered the gold-standard intervention for these clinical challenges. Methods We undertook a systematic review of the literature regarding TEVAR intervention in co-TBAD and un-TBAD. A comprehensive search was undertaken across four major databases and was evaluated and assessed until June 2020. Results A total of 16,104 patients were included in the study (7772 patients co-TBAD and 8352 un-TBAD). A significantly higher proportion of comorbidities were seen in co-TBAD patients compared with un-TBAD. Acute dissection was more frequent in the co-TBAD group (73.55% vs. 66.91%), while chronic dissection was more common in un-TBAD patients (33.8% vs. 70.73%). Postprocedure stroke was higher in co-TBAD (5.85% vs. 3.92%; p < .01), while postprocedural renal failure was higher in un-TBAD patients (7.23 vs. 11.38%; p < .01). No difference was observed in in-hospital mortality however the 30 days mortality was higher in the co-TBAD group. One-year survival was higher in the uncomplicated group but this difference was not observed in the 5-year survival. Conclusion In our analysis we can appreciate that despite significantly higher comorbidities in the co-TBAD cohort, there was no difference in in-hospital mortality between the two groups and the 5-year survival did not have any difference.

21 June 2018 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
AHAmer Harky
Amer Harky
AHAlexander Hof
Alexander Hof
MGMegan Garner
Megan Garner
SFSaied Froghi
Saied Froghi
MBMo Bashir
Mo Bashir

21 February 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
MJMatti Jubouri
Matti Jubouri
MAMohammed Al-Tawil
Mohammed Al-Tawil
HYHo Cheung Anthony Yip
Ho Cheung Anthony Yip
ABAli Bashir
Ali Bashir
STSven Z. C. P. Tan
Sven Z. C. P. Tan
IWIan Williams
Ian Williams

10 March 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MJMatti Jubouri
Matti Jubouri
FKFatima Kayali
Fatima Kayali
PSPriyanshu Saha
Priyanshu Saha
DADaniyal M. Ansari
Daniyal M. Ansari
YRYousef Rezaei
Yousef Rezaei
MBMo Bashir
Mo Bashir
Background: The introduction of the frozen elephant trunk (FET) technique for total arch replacement (TAR) has revolutionized the field of aortivascular surgery by allowing hybrid repair of complex aortic pathologies in a single step through combining an open surgical approach with an endovascular one. FET has been associated with favorable aortic remodeling, however, its is also associated with development of distal stent graft induced new entry (dSINE) tears postoperatively. The rate of aortic remodeling and the incidence of dSINE have been linked together, in addition, there seems to be a relationship between these two variables and FET insetion length as well as graft size. Aims: The scope of this review is to highlight the rate of aortic remodeling as well the incidence of dSINE associated with different FET devices available commercially. This review also aimed to investigate the relationship between aortic remodeling, dSINE, FET insertion length and FET graft size. Methods: We conducted a comprehensive literature search using multiple electronic databases including PubMed, Ovid, Scopus and Embase in order to collate all research evidence on the above mentioned variables. Results: Thoraflex™ Hybrid Plexus seems to yield optimum aortic remodeling by promoting maximum false thrombosis as well true lumen expansion. Thoraflex Hybrid™ is also associated with the lowest incidence of dSINE post-FET relative to the other FET devices on the market. Aortic remodeling and dSINE do influence each other and are both linked with FET graft length and size. Conclusion: The FET technique for TAR shows excellent aortic remodeling but is associated with a considerable risk of dSINE development. However, Thoraflex™ Hybrid has demonstrated itself to be the superior FET device on the aortic arch prostheses market. Since aortic remodeling, dSINE, FET insertion length and stent graft size are all interconnect, the choice of FET device length and size must be made with great care for optimum results.

24 October 2018 in Vascular Medicine
Verified
Journal Article
Closed access
AHAmer Harky
Amer Harky
MFMatthew Fok
Matthew Fok
DBDamian Balmforth
Damian Balmforth
MBMo Bashir
Mo Bashir
Despite being recognised over a century ago, the aetiology and pathogenesis of large vessel vasculitis (LVV) still remains elusive. Takayasu’s arteritis (TA) and giant cell arteritis (GCA) represent the two major categories of LVV, each with distinctive clinical features. Over the last 10 years an increased understanding of the immunopathogenesis of the inflammatory cascade within the aortic wall has revived the view that LVVs may represent subtypes of the same pathological process, with implications in the treatment of this disease. In this review, the histological, genetic and immunopathological features of TA and GCA will be discussed and the evidence for a common underlying disease mechanism examined. Novel markers of disease activity and therapies based on advances in our understanding of the immunopathogenesis of these conditions will also be discussed.